Clinical Trial Flow Charts
Open and Pending Trials
9/18/2019

Oncology Trials

1. Brain Cancer .................................................................2
2. Breast Cancer ...............................................................3-5
3. GI Cancer .......................................................................6-9
4. GU Cancer .....................................................................10-12
5. GYN Cancer ....................................................................13-14
6. Head and Neck Cancer ...................................................15
7. Melanoma and Sarcoma ................................................16-17
8. Thoracic Cancer ...........................................................18-19

HMCT Trials

9. Leukemia .........................................................................20-21
10. Lymphoma ......................................................................22-23
11. Myelodysplastic Syndromes (MDS) ..............................24
12. Myeloproliferative Neoplasms (MPN) ............................25
13. Myeloma ........................................................................26
Brain Cancer

Low Grade

Newly Dx

Recurrent GBM

No trials

Grade 3

TAS 120
HSC: 142341
PI: Al-Rajabi

CPX-POM-001
HSC: 143134
PI: Taylor

2102-ONC-102
HDC: 143250
PI: Al-Rajabi

No trials

Grade 4

TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations

Ph. 1 study of CPX-POM in Patients with Advanced Solid Tumors

A Ph. b/2 Study of FT-2102 in Pts. w/ Adv. Sol- id Tumors & Gliomas with an IDH1 Mu-tation

CRC, WW/Hos Consent

CRC, WW

CRC, KUH, WW Consent

New DX, Grade II

BN003
HSC: 143243
PI: Wang
SC: Chris

NCI 10186
HSC: 143671
PI: Salacz

A Ph. I/II Study of Nivolumab plus or minus Ipilimumab in Combo w/ Multi-fraction Stereotactic Radiosurgery for Recurrent High-grade Radiation-relapsed Meningioma.

KUH, WW, CCP

KUH, WW

Meningioma

Multi Diseases

No trials

High Grade

ICP

IIT

P53Atorva

Atorvastatin in Tumor Protein 53 (p53) - Mutant and p53 Wild-Type Mals.

CRC, KUH, CCP, WW Consent

Please use email address below for referrals

EP Referrals Email/Link (at CRC)
KUCCCTOEarlyPhaseTrialReferral@kumc.edu

Neuro/Brain Referrals Email/Link:
KUCCCTONEUROTrialReferral@kumc.edu
<table>
<thead>
<tr>
<th>Study Code</th>
<th>Status</th>
<th>HSC Code</th>
<th>PI</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>STX0115_S</td>
<td></td>
<td></td>
<td></td>
<td>GI Cancers</td>
</tr>
<tr>
<td>IRCCA 143493 PI: Al-Rajabi</td>
<td></td>
<td></td>
<td></td>
<td>Bile Duct</td>
</tr>
<tr>
<td>INCB 54828-302 HSC: 143493 PI: Al-Rajabi</td>
<td></td>
<td></td>
<td></td>
<td>1st line</td>
</tr>
<tr>
<td>SX1606.1-207-BTC HSC: 144232 PI: Al-Rajabi Status: 8.19 need ICF from SP</td>
<td></td>
<td></td>
<td></td>
<td>2nd line</td>
</tr>
<tr>
<td>D933AC000 01 Topaz 1 HSC: 144447 PI: Sun Status: 8.22 CF to finance</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NuTide:121 HSC: tba PI: Al-Rajabi Status: ERC approved</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAS 120-101 HSC: 142341 PI: Al-Rajabi</td>
<td></td>
<td></td>
<td></td>
<td>HCC</td>
</tr>
<tr>
<td>CA209-9DX HSC: 142160 PI: Al-Rajabi</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D910DC0001 HSC: 144417 PI: Al-Rajabi Status: 8.21 CF to SP &amp; PI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MK7902-002 HSC: 143740 PI: Al-Rajabi</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIT-2017-Cabozant DurvaGI HSC: 141879 PI: Saeed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>POLARIS 2013-001 HSC: 143240 PI: Al-Rajabi</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please use email address below for referrals

EP Referrals Email/Link (at CRC)
KUCCCTOEaryPhaseTrialReferral@kumc.edu

GI Referrals Email/Link:
KUCCCTOGITrialReferral@kumc.edu
GYN Cancers

Ovarian/Peritoneal/Fallopian

1st line

Recurrent

Plat. Sensitive

NRG-GY0016
HSC: 142774
Pl: Jewell
Pembrolizumab & Epacadostat in Pts w/ Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma

NRG-GY0009
HSC: 143483
Pl: Jewell
Pegylated Lipoosomal Doxorubicin Hydrochloride w/ Atezolizumab and/or Bevacizumab in Treating pts w/ Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CA

10017
HSC: 141975
Pl: Jewell
Ovarian Cancer Pts Evaluating Rucaparib & Nirbulumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemo

Platinum Resistant

VR-111-701
HSC: 143198
Pl: Jewell
VB-111 With Paclitaxel vs Paclitaxel for Tx of Recurrent Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen

SGNTV-002
HSC: 143494
Pl: Jewell
Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen

GCT1015-05
HSC: 143379
Pl: Jewell
Tisotumab Vedotin (HuMax-TF-ADC) in Combo w/ Other Agents in Subjects w/ Recurrent or Stage IVB Cervical Cancer

Cervical/Vaginal

1st line

2nd line +

No trials

GOG-3020 ATHENA
HSC: 142720
Pl: Jewell
Ovarian Cancer Pts Evaluating Rucaparib & Nirbulumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemo

GOG-GY0016
HSC: 143483
Pl: Jewell
Pembrolizumab & Epacadostat in Pts w/ Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma

Please use email address below for referrals

EP Referrals Email/Link (at CRC)
KUCCCTOEaryPhaseTrialReferral@kumc.edu

GYN Referrals Email/Link:
KUCCCTOGYNTrialReferral@kumc.edu
GYN Cancers

Endometrial

1st line

No trials

CRC (WW Consent)

2nd line +

4010-01-001
HSC: 141177
PI: Jewell
Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET)

Only endometrial cancer pts (MSS or MSI)

CRC

10104
HSC: 142208
PI: Jewell
Cabozantinib & Nivolumab in Treating Patients With Adv., Recurrent or Metastatic Endometrial Cancer

NRG-GY018
HSC: tba
PI: Jewell
Status: ERC approved 9.9

Pembrolizumab in Addition to Paclitaxel & Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

CRC

Cancer Referrals Email/Link: KUCCCTOGYNTrialReferral@kumc.edu

Please use email address below for referrals

EP Referrals Email/Link (at CRC)
KUCCCTOEarlyPhaseTrialReferral@kumc.edu

GYN Referrals Email/Link:
KUCCCTOGYNTrialReferral@kumc.edu

Multi Diseases

17-262-01
HSC: 143248
PI: Baranda
Status: 9.10 pending activation

NKTR-262 in Combo With NKTR-214 and W/NKTR-214

Plus Nivolumab in Pts W/ Locally Adv. or Met. Ovarian (REVEAL)

140807
HSC: 141107
PI: Wil-liamson
Carboplatin in Adv. Pts With Adv. or Met. Solid Tumors

141177
HSC: 144273
PI: Baranda
Cemiplimab in Pts With Adv. Solid Tumors & combo w/ Atezi-
lumab to Pts With Locally Adv. or Met. Solid Tumors (DUET-2) - Endometrial

142208
HSC: tba
PI: Jewell
Status: ERC approved 9.9

Nivolumab and Ipilimumab in Treating Patients With Re-
tion

CRC, MCA

CRC, WW Consent

CRC, WW

TCD1467
HSC: 142212
PI: Wil-liamson
FN-1501 in patients with adv. solid tumors

FN-1501
HSC: 142092
PI: Wil-liamson
FN-1501 mono-
otherapy in pa-
tients with adv.
solid tumors

CRC, WW Consent

CRC, WW Consent

CRC, WW

ITT-2016-
Epaca-
dostat
HSC: 142313
PI: Jewell
Atorvastatin in Tumor Protein 53 (p53) - Mutant and p53 Wild-
Type Mals.

S1609-
DART
HSC: 142126
PI: Al-Rajabi
Epacadostat (INCB24360) in combination with sirolimus in adv.
Malignancies

CRC

CRC

CRC

CRC, WW Consent

CRC, WW Consent

CRC

8374-CL-
0101
HSC: 142212
PI: William-
son
ASP8374, an Immune Checkpoint Inhibitor, in Pts With Adv.
Sol-
id Tumors

Xl184-
021
HSC: 142803
PI: Baranda
Cabozan-
tinib in Combo W/ Atezoli-
mab to Pts With Adv.
Solid Tumors

XmAb207-
017
HSC: 142507
PI: Baran-
da
Cabozan-
tinib

CRC

CRC

CRC

CRC

CRC, MCA

CRC, WW Consent

CRC, WW Consent

CRC

141902
HSC: 142316
PI: William-
son
DCC-2036-01-
003
HSC: 143936
PI: Jewell
Status: pending SIV

Rebavirin (DCC-2036) in combo W/ Paclitaxel in Pts With Adv. or Met. Solid Tumors

DCC-2036-
004
HSC: 143939
PI: Jewell
Status: pending SIV

Rebavirin (DCC-2036) in combo W/ Carboplatin in Pts With Adv. or Metastatic Solid Tumors

TED15297
HSC: 144723
PI: Baranda
Status: PRMC 7.11

Intratumoral Administration of SAR441000 as Monotherapy & combo w/ Cemiplimab in Pts With Adv. Solid Tumors

INCMGA 0012-
105
HSC: 141899
PI: Baranda
Status: PRMC meeting 8.27

Intratumoral Administration of SAR441000 as Monotherapy & combo w/ Cemiplimab in Pts With Adv. Solid Tumors (POD1UM-105)

CRC

CRC

CRC, WW Consent

CRC, WW Consent

CRC, WW

CRC
Please use email address below for referrals

EP Referrals Email/Link (at CRC)
KUCCCTOEarlyPhaseTrialReferral@kumc.edu

Hem Referrals Email/Link:
KUCCCTOHemTrialReferral@kumc.edu

Cell Therapy Referrals Email/Link:
KUCCCTOCellTherapyTrialReferral@kumc.edu
Asst. Project Mgrs: Marc Morrison, Melody Kabrey
Early Phase Project Director: Adam AlDouri

Please use email address below for referrals

EP Referrals Email/Link (at CRC)
KUCCCTOEarlyPhaseTrialReferral@kumc.edu

Hem Referrals Email/Link:
KUCCCTOHEMTrialReferral@kumc.edu

Cell Therapy Referrals Email/Link:
KUCCCTOCelTherapyTrialReferral@kumc.edu

BMT Referrals Email/Link:
KUCCCTOBMTTrialReferral@kumc.edu